Sociodemographic profile of mortality from acute myeloid leukemia in the regions of Brazil: an ecological study
DOI:
https://doi.org/10.17058/reci.v16i.20616Keywords:
Leukemia myeloid acute, Mortality, Health profileAbstract
Background and Objectives: Acute myeloid leukemia (AML), although a rare neoplasm, is the most common and aggressive type of the disease in adults. To date, no studies have analyzed the profile of acute myeloid leukemia in the general population across the entire Brazilian territory for the proposed period. This study aimed to analyze the epidemiological profile of AML in the five regions of Brazil between 2014 and 2023. Methods: This is an ecological study based on the Mortality Information System (SIM) available in DATASUS. Deaths for which the underlying cause was classified as acute myeloid leukemia were selected across the Brazilian regions for the period from 2014 to 2023. The variables included were age group, sex, race, year of death, and educational level. After data collection, the information was organized in an Excel spreadsheet, and descriptive statistics were performed. Results: A total of 33,596 deaths were recorded during the period, with a predominance in the Southeast Region (47.7%) and a progressive increase in deaths, peaking in 2023. Higher mortality was observed among men (52.5%), white individuals (61%), those aged 70 to 79 years (21.1%), and individuals with 8 to 11 years of schooling (23.9%). Conclusion: Thus, the importance of this research is highlighted in guiding effective public policies for the most affected populations and regions, with the aim of reducing mortality through early therapy and the optimization of healthcare resources.
Downloads
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660.
2. Palmieri R, Candoni A, Di Raimondo F, et al. Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy. Blood Reviews. 2025 Apr;101288. https://doi.org/10.1016/j.blre.2025.101288.
3. Pelcovits A, Niroula R. Acute myeloid leukemia: a review [Internet]. R I Med J. 2020 Apr;103(4):38-40. Available from: http://rimed.org/rimedicaljournal/2020/04/2020-04-38-hem-onc-pelcovits.pdf.
4. Barry DL, Enjeti AK, Lincz LF, Skelding KA. Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer [Internet]. 2025 Jun 26;1880(4):189377. https://doi.org/10.1016/j.bbcan.2025.189377.
5. Simão F. Panorama da atenção de leucemia mieloide aguda no SUS [Internet]. Observatório de Oncologia; 2023. Available from: https://observatoriodeoncologia.com.br/estudos/panorama/2023/panorama-da-atencao-de-leucemia-mieloide-aguda-no-sus/.
6. Correa N. Tendências da mortalidade por leucemia no Brasil [Internet]. Observatório de Oncologia; 2020. Available from: https://observatoriodeoncologia.com.br/estudos/cancer-de-sangue/leucemias/2020/mortalidade_leucemias/.
7. Ribeiro CM, Atty ATM. Efeitos da Covid-19 na atenção ao câncer no Brasil: impactos do rastreamento ao tratamento. Rev Bras Cancerol [Internet]. 2025;71(1). https://doi.org/10.32635/2176-9745.RBC.2025v71n1.4848.
8. Mantovani M, Ynoue D, Guedes M, et al. Leucemias mieloides: avaliação epidemiológica no Brasil. Hematol Transfus Cell Ther. 2024;46(Suppl 3):S455-6. https://doi.org/10.1016/j.htct.2024.09.765.
9. Salvaro M, Frassetto M, Just M, et al. Leucemia mieloide aguda: perfil clínico-epidemiológico no Brasil entre 2009 e 2019. Hematol Transfus Cell Ther. 2021;43(Suppl 1):S505-6. https://doi.org/10.1016/j.htct.2021.10.871.
10. Fernandes M, Lucini C, Almeida I, Pinheiro L, Fernandes F. Perfil de óbito por leucemia mieloide aguda nos últimos 10 anos no Brasil. Hematol Transfus Cell Ther. 2024;46(Suppl 5):S1145. https://doi.org/10.1016/j.htct.2024.09.2002.
11. American Cancer Society. About acute myeloid leukemia (AML) [Internet]. Atlanta: American Cancer Society; 2019. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8674.00.pdf.
12. Nielsen LH, Frederiksen H, Madanat-Harjuoja LM, et al. Socioeconomic status and overall survival among patients with hematological malignant neoplasms. JAMA Network Open [Internet]. 2024 Mar 4;7(3):e241112. https://doi.org/10.1001/jamanetworkopen.2024.1112.
13. Ribeiro CM, Atty ATM. Efeitos da Covid-19 na atenção ao câncer no Brasil: impactos do rastreamento ao tratamento. Rev Bras Cancerol. 2025;71(1). https://doi.org/10.32635/2176-9745.RBC.2025v71n1.4848.
14. Mantovani M, Ynoue D, Guedes M, et al. Leucemias mieloides: avaliação epidemiológica no Brasil. Hematol Transfus Cell Ther. 2024;46(Suppl 3):S455–6. https://doi.org/10.1016/j.htct.2024.09.765
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Caroline Carraro, Mariana Salmoria Ceron, Raquel Aparecida Bertola Rodrigues Rêgo, Daniely Sampaio Arruda Tavares
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author must state that the paper is original (has not been published previously), not infringing any copyright or other ownership right involving third parties. Once the paper is submitted, the Journal reserves the right to make normative changes, such as spelling and grammar, in order to maintain the language standard, but respecting the author’s style. The published papers become ownership of RECI, considering that all the opinions expressed by the authors are their responsibility. Because we are an open access journal, we allow free use of articles in educational and scientific applications provided the source is cited under the Creative Commons CC-BY license.
